In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on AIM ImmunoTech (AIM – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $0.67.
McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Capricor Therapeutics, and VistaGen Therapeutics. According to TipRanks, McCarthy has an average return of -38.8% and a 13.90% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AIM ImmunoTech with a $3.00 average price target.
See the top stocks recommended by analysts >>
AIM market cap is currently $31.95M and has a P/E ratio of -1.74.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
Read More on AIM:
- Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share
- Analysts Offer Insights on Consumer Goods Companies: Harvey Norman Holdings Ltd (OtherHNORF) and The Swatch Group (OtherSWGAF)
- Investigation of Potential Copper Porphyry Systems now Underway at First Tellurium’s Deer Horn Property
- Mizuho Securities Sticks to Their Buy Rating for Assembly Biosciences (ASMB)
- New Buy Rating for MongoDB (MDB), the Technology Giant
